The signing ceremony for CStone Pharmaceuticals‘ Global R&D Headquarters and Industrialization Base took place in Suzhou on August 6. The event marks the building of another state-of-the-art research and development (R&D) center and manufacturing facility in Suzhou. 
 
According to the agreement, the construction of the site, with a planned building area of approximately 100,000m², will be commissioned to a third party and is scheduled to break ground in 2020. Once completed, the complex will be equipped with integrated capabilities for R&D, Pilot Plant, and full commercial scale manufacturing, which will have a production capacity of 26,000L for macromolecule biologics and 1 billion tablets and capsules for small molecule drugs.
 
“The Suzhou Industrial Park has in recent years created a vibrant innovation-driven biopharmaceutical ecosystem through its effective promotion of emerging strategic industries. Since its inception in 2016, CStone has received tremendous support from the Suzhou Industrial Park. We are highly confident in SIP’s policy environment and infrastructure, and have therefore chosen Suzhou as our global headquarters for R&D and manufacturing. With a strong base in Suzhou, CStone aims to become globally recognized as a leading biopharmaceutical company in China and make significant contributions to the sector in Suzhou and nationwide,” said Dr. Frank Jiang, Chairman and CEO of CStone.